
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.0% | 10.975 | 10.75 | 11.20 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0146 | -7.51 | 89.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/7/2023 05:02 | Ruck sorry but I saw your 4649 as personal - you didn't comment at all on the point I had made BUT took the chance to poke again at the non-existent 'Club'. Oblique maybe, but a sneer nonetheless. | ![]() torquayfan | |
11/7/2023 23:17 | Inanaco - LD seemed pretty cleari the interview. Modi1 needs CI. Maybe modi2 will work as monotherapy but modi1 is not. | knowlesi | |
11/7/2023 22:39 | Actually ruck, he is quite specifically talking about the trial, and he purchased during the very euphoria he describes. No doubt if the shares were now 35p we'd all be hearing about the amazing 22p trade.... "I recall the great euphoria over the initial partial tumour reduction in HNC and the predictions of complete elimination with higher dose rates.Well sadly that does not seem to have occurred or even repeated in similar cases.That is why it is always better to be cautious in interpreting any small cohort numbers.." | ![]() wigwammer | |
11/7/2023 22:08 | Wiggy, I think the restraint Ivy (and others) have suggested is not in their own investments but in trying to convince others that they should, in Lozan's words, BUY BUY BUY. I think the events of the past 11 years have dispelled the myths of "no risk" and "safe as drinking water" | ![]() ruckrover | |
11/7/2023 21:56 | Hmm... No, ivyspivey... The point is you are trying to dish out lessons in restraint. But you were anything but restrained when you purchased shares at 22p in the middle of the "hype" as you describe it, and then reported the trade here. It's really that simple. ATB | ![]() wigwammer | |
11/7/2023 21:51 | Dear oh dear, looks like Lindy the Nobel Prize winner in waiting has had a reality check. Normally the interviewers are excited by the products their guests are talking about, this bloke is not remotely moved or excited. Surprised none of you connected the dots when goodfellow left, a red flag if ever there was one. why would he wait 10 years for Modi and jump ship within months, answer it is nowhere near living up to the hype and expectations. Maybe Lindy will come up with another serendipitous discovery that will take ten years to get into the clinic and be another damp squib. Moditope was a great product on a computer screen not so good in real life experiments. At least it is safe but so is a placebo, ask Pfizer. | ![]() panama7 | |
11/7/2023 21:45 | You can repeat the point as much as you like. Your mate Nana bought shares at 44p and told everyone about it so by that logic you should not be taking any lessons from him either.Point being it is totally irrelevant who bought what when as it is only applicable at that point in time. GLA | ![]() ivyspivey | |
11/7/2023 21:29 | I repeat the point, ivyspivey. You purchased scancell shares at 22p and told this board all about it. So I'm not sure anyone should be taking lessons in caution and restraint from you... ATB | ![]() wigwammer | |
11/7/2023 19:58 | And bang on cue there we have it again from 'cleanerworld'..lol' Frustration the market has not picked up on 44% stable... Yes it's all hush hush isn't it..lol If only it were in the public domain, the world would think just like 'cleanerworld'... Or...perhaps NOT. | ![]() 2tyke | |
11/7/2023 19:53 | She has options to exercise and a capital gain to firm up..... | ![]() markingtime | |
11/7/2023 19:25 | Lozan, The reason that toys are being thrown is that the clapping brigade are being forced to come to terms with their flawed beliefs. We've had to read all the nonsense for so long now...too risky being out with news coming....follow the science...the traders are wrong....blah blah. They now have to face upto the fact that despite all the encouraging news since late lsst year, the share price trajectory was completely correct. It was their 'opinions' that were wrong. Of course, peeps in denial will spin the narrative to try and save face and avoid actually learning something 'useful'.Peeps like inanaco are beyond reason anyway. The market is a place of irony...and complete contradiction. | ![]() 2tyke | |
11/7/2023 19:04 | Miavoce, Stock markets never whisper....they speak volumes. Price and trend is ALWAYS correct...by definition. It's PI opinions that should be whispered. | ![]() 2tyke | |
11/7/2023 17:55 | Ivy 4659 - Spot on . There does seem to be a danger from the number of 'dummies and toys' being spit out / thrown out of the prams of the 'trHYPE party' | ![]() the real lozan | |
11/7/2023 17:38 | Ivy give it a break. It's not 'so be it' but how I saw it. Your style has changed markedly in recent months. Like 'posing' . . . a bit 'chippy'. ATB | ![]() torquayfan | |
11/7/2023 17:29 | Evening TF- if you think LD was fine then so be it I will await the Investor Meet event to look again at her “ demeanour “ and happy to judge accordingly. I just did not sense any excitement which I found surprising given the so called AGM inference that had her barely able to contain her thoughts on the likely next meaningful update which we got yesterday. I recall the great euphoria over the initial partial tumour reduction in HNC and the predictions of complete elimination with higher dose rates.Well sadly that does not seem to have occurred or even repeated in similar cases.That is why it is always better to be cautious in interpreting any small cohort numbers and our prime aim is for those on the trial to reap the benefits. Of course there have been good results in these very difficult to treat cancers and that is to be welcomed but this is a salutary lesson for those that have difficulty in restraining themselves from attempting to heighten expectations based on a misunderstanding of the trial process and/ or a wish for personal gain. Now that we have a fuller understanding of the actual results and hopefully we will have a TD report to further validate the Modi findings we can make a much better judgement about the likely future share price The market has given its reaction and once again it lends credence towards the ones who called for caution rather than the hyper optimistic but whether they will learn their lesson is debatable but no matter we all know who is most comfortable with their holdings here | ![]() ivyspivey | |
11/7/2023 17:12 | Less than £60k worth of trades today, if the market is saying anything it is whispering.... | ![]() miavoce | |
11/7/2023 17:11 | It’s endless story and feels like tasteless chewing gum. It might be good opportunity for c100m but shambolic management and all last recruit is abysmal. | ![]() golcheja | |
11/7/2023 17:05 | gol - you can't read that RNS and think you are not getting a huge amount of opportunity for c.£100m whether the market values it or not is somewhat irrelevant unless they want to do an urgent equity raise and we know that isn't necessary. | ![]() nigelpm | |
11/7/2023 17:04 | CFO? Too late next fund raising will be at 3p. I want be tempted. | ![]() golcheja | |
11/7/2023 16:58 | Inan, prepare for a massive drop in value. | ![]() golcheja | |
11/7/2023 16:56 | Market reaction a sliming down the trial points to disappointing result. Doesn’t matter a wig what Marcus and other learned folks keep on posting, this will continue to sink. Why I’m not surprised. | ![]() golcheja |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |